Aziz Mottiwala - Sep 10, 2021 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Commercial Officer
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Sep 10, 2021
Transactions value $
-$57,435
Form type
4
Date filed
9/14/2021, 04:51 PM
Next filing
Nov 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise $47.8K +4.35K +8.08% $10.99 58.2K Sep 10, 2021 Direct
transaction TARS Common Stock Options Exercise $1.17K +2.59K +4.46% $0.45* 60.8K Sep 10, 2021 Direct
transaction TARS Common Stock Sale -$57.4K -2.59K -4.27% $22.15 58.2K Sep 10, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Employee Stock Option (right to buy) Options Exercise -$47.8K -4.35K -22.49% $10.99 15K Sep 10, 2021 Common Stock 4.35K $10.99 Direct F2
transaction TARS Employee Stock Option (right to buy) Options Exercise -$1.17K -2.59K -77.06% $0.45* 772 Sep 10, 2021 Common Stock 2.59K $0.45 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $22.000 to $22.200. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020.
F3 Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter.